Skip to main content
Equibles
SNGX logo

SNGX · Soligenix, Inc. · Metrics

Track SNGX — free

Use SNGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SNGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.35 +0.01 (+3.17%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, as of the date of this filing, the Company continues to explore various strategic alternatives but has not consummated any transaction or obtained any additional program assets to develop which raises substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 7, 2026
Market Cap
$7.48M
Shares
21.77M
Volume · Oct 20 81.01K Avg daily vol (3M) 222.33K

SNGX metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.35
Market cap
$7.48M

Price action

20 metrics
Price change (1W)
-2.3%
Price change (30D)
-7.6%
Price change (3M)
-4.5%
Price change (6M)
-75.1%
Price change (YTD)
-74.4%
Price change (1Y)
-79.2%
Trailing year
Price change (5Y)
—
52-week high
$1.70
52-week low
$0.28
Change from 52-week high
-79.8%
Change from 52-week low
+22.8%
Annualized volatility
131.2%
Annualized volatility (3M)
39.5%
Beta
2.1
RSI (14D)
41.1
Price vs SMA 50
-7.7%
Price vs SMA 200
-52.8%
Avg volume (3M)
226,581
Relative volume
0.3
Average dollar volume
$84,932

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
21.77M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.5×
reciprocal yield 197.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
15.5×
reciprocal yield 6.4%
P / book
1.2
reciprocal yield 86.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-133.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.1×
reciprocal yield 93.8%
EV / revenue historical average (5Y)
1.1×
reciprocal yield 93.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-7,907.7%
Trailing 12 months
Net margin
-6,925.1%
Gross profit (TTM)
$97,311
Operating profit (TTM)
−$11.04M
Net income (TTM)
−$10.24M
Trailing 12 months
Diluted EPS (TTM)
$-0.75
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.76
Gross profit per diluted share (TTM)
$0.29
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$-86.25
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.52

Growth

11 metrics
Revenue growth YoY
-98.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$494,623
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+386.5%
Year over year · more shares
Revenue CAGR (3Y)
-47.5%
Revenue CAGR (5Y)
-51.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-154.1%
Return on assets
-97.5%
Debt / equity
0.0
Current ratio
2.8
EBITDA (TTM)
−$15.02M
Free cash flow (TTM)
—
Quick ratio
2.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$9.81M
Latest balance sheet
Cash & equivalents
$9.81M
Total assets
$10.50M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$9.74M
Capital expenditures (TTM)
—
R&D (TTM)
$6.62M
SG&A (TTM)
—
Stock compensation (TTM)
$661,651
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
17
13F filer change QoQ
+2
Institutional ownership
4.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.3%
Private-fund adviser ownership
1.4%
Active holders' share change QoQ
+2,510.4%
Holder tenure
2.5
Price vs estimated holder cost
-55.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.8%

Short interest

3 metrics
Short interest
0.8%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 812796 CUSIP 834223604 13F (30d) 1 filings 1 filers Visit website Investor relations